TransThera Sciences (Nanjing) (2617 HK)

Analysis

Health Care • China

TransThera Sciences (Nanjing) Inc. is a China-based biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. Its core product, Tinengotinib (TT-00420), is a multi-targeted kinase (MTK) inhibitor in clinical stages for treating relapsed or refractory, drug-resistant solid tumors. The company is headquartered in Nanjing, China, and was founded in 2014.

Refresh

Company Event • 30 Mar 2027 16:00 • Upcoming

Add To Calendar

H2 2026

Company Event • 28 Aug 2026 16:00 • Upcoming

Add To Calendar

H1 2026

Company Event • 31 Mar 2026 16:00 • Upcoming

Add To Calendar

H2 2025

Company Event • 25 Aug 2025 16:00 • Upcoming

Add To Calendar

H1 2025

No more events

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00